You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Compact Energy Conversion Module
SBC: Extreme Diagnostics, Inc. Topic: T301This STTR project delivers a compact vibration-based Energy Conversion Module (ECM) that powers sensors for purposes like structural health monitoring (SHM). NASA customers include the ISS and the Orion deep space vehicle, both of which need wireless sensors to monitor and assess structural health. The ECM represents a significant advancement in the use of wireless and self-powered devices by enab ...
STTR Phase I 2014 National Aeronautics and Space Administration -
High Performance Nanolauncher
SBC: Orbital Technologies Corporation Topic: T101The proposed Low Cost Nanolauncher (LCN) is an upper stage using a new, inexpensive propulsion system. The Phase I program will combine several technologies with a simple design strategy to produce a flight-weight propulsion system that is easy to fabricate and operate. Self pressurizing propellants will minimize complexity of the propulsion system and vortex cold-wall technology will be used to ...
STTR Phase I 2014 National Aeronautics and Space Administration -
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto
SBC: Nirvana Sciences, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Orally available transition state inhibitors for triple negative breast cancer
SBC: NANOMETICS LLC Topic: NCIProblem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer
SBC: CUREFAKTOR PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Modified RNA tools and diagnostics for drug abuse
SBC: ATHGHIN BIOTECHNOLOGY, INC. Topic: NIDADESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Smartphone Help for DWI Offenders and Their Families: A B-SMART App
SBC: KLEIN BUENDEL, INC. Topic: NIAAADESCRIPTION (provided by applicant): Driving while intoxicated (DWI) remains a substantial and preventable source of morbidity and mortality in the United States. A variety of sanctions and interventions have been attempted to reduce DWI in the U.S., including enhanced DWI enforcement efforts, stricter drunk driving laws, responsible alcohol beverage service training, and alcohol treatment. The Ig ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIADESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Testing Smad7-based biologics for treating chronic wounds
SBC: Taiga Biotechnologies, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): Chronic skin wounds associated with various diseases (e.g., diabetes) and aberrant healing from acute wounding (e.g., hypertrophic scarring) is a major health care burden, which need scientific discovery-based therapeutic interventions. Our previous studies show that Smad7, a TGFb signaling antagonist, accelerates skin wound healing. We have developed a Smad7 f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health